表紙
市場調査レポート

世界の経皮ドラッグデリバリー市場:戦略的分析、技術、競合企業プロファイル、財務評価、製品パイプライン評価およびSWOT研究

GLOBAL TRANSDERMAL DRUG DELIVERY MARKET to 2020 Strategic Analysis, Technologies, Competitor Profiles, Financial Evaluation, Product Pipeline Assessment and SWOT Investigation

発行 Kelly Scientific Publications 商品コード 320895
出版日 ページ情報 英文 280 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
世界の経皮ドラッグデリバリー市場:戦略的分析、技術、競合企業プロファイル、財務評価、製品パイプライン評価およびSWOT研究 GLOBAL TRANSDERMAL DRUG DELIVERY MARKET to 2020 Strategic Analysis, Technologies, Competitor Profiles, Financial Evaluation, Product Pipeline Assessment and SWOT Investigation
出版日: 2015年02月20日 ページ情報: 英文 280 Pages
概要

当レポートでは、世界の経皮ドラッグデリバリー市場における市場規模、区分、主要企業、SWOT分析、影響を及ぼす技術および事業・経済環境について包括的に分析し、お届け致します。

第1章 エグゼクティブサマリー

第2章 経皮ドラッグデリバリー

  • イントロダクション
  • これまでの経皮ドラッグデリバリーの発展
  • 皮膚:生体構造・生理機能
  • 経皮ドラッグデリバリーの影響因子
  • 経皮ドラッグデリバリーを強化する戦略
  • 経皮デリバリーとその他の手法との比較
  • 経皮ドラッグデリバリーのメリット
  • 経皮デリバリーのデメリット
  • 経皮治療の合併症

第3章 経皮ドラッグデリバリーに影響する生物力学および薬理学要素

  • 経皮ドラッグデリバリーの影響因子
  • 経皮ドラッグの設計
  • 市販の経皮ドラッグ検査用皮膚モデル
  • 経皮ドラッグデリバリーシステムの体外検査

第4章 経皮ドラッグデリバリー技術

  • イントロダクション
  • 小胞性経皮キャリア
  • 経皮パッチ
  • パッチレス経皮デリバリーシステム
  • 定量経皮システム
  • 経皮ドラッグデリバリー向けポリマー
  • 経皮デリバリーを促進する物理的手法
  • 電気泳動およびイオン導入はどのようにドラッグデリバリーに影響を及ぼすか、ほか

第5章 ナノテクノロジーはいかにして経皮ドラッグデリバリーを転換したか

  • 概要
  • ナノテクノロジー型の経皮ドラッグデリバリー
  • 皮膚疾患向けナノ粒子・ナノ乳液
  • ナノパッチ
  • Inocyte:表皮性ドラッグデリバリーシステム、ほか

第6章 経皮ドラッグデリバリーおよび病状

  • アンチエイジング製品
  • がん
  • 心血管疾患
  • 慢性疲労症候群
  • 避妊、ほか

第7章 遺伝子治療および経皮ドラッグデリバリー

  • 概要
  • プラスミドDNAおよびエレクトロポレーション
  • アンチセンス療法

第8章 ワクチンおよび経皮ドラッグ技術

  • イントロダクション
  • 現在の技術
  • 経皮ワクチンの用途

第9章 世界のドラッグデリバリー市場

  • 概要・分析
  • 米国のドラッグデリバリー市場
  • 欧州のドラッグデリバリー市場
  • 新興のドラッグデリバリー市場
  • 先進ドラッグデリバリー情勢

第10章 経皮ドラッグデリバリー企業のビジネスプロファイルおよび戦略的評価

  • Actavis
  • Actelion
  • GlaxoSmithKline
  • Bayer
  • Mylan Pharmaceuticals
  • Novartis
  • Upsher-Smith
  • Ascend Therapeutics
  • AMAG Pharmaceuticals (Lumara Health, KV Pharma/Ther-Rx Corp)
  • Janssen Pharmaceuticals
  • Noven Pharmaceuticals
  • ProStrakan
  • Shire
  • Hercon Pharmaceutical
  • Kremers Urban Pharmaceuticals
  • Nitto Denko
  • Teva Pharmaceutical Industries
  • Endo International
  • Teikoku USA
  • Boehringer Ingelheim
  • 3M
  • UCB
  • ParPharm

第11章 経皮ドラッグデリバリー企業の財務分析

  • Actavis
  • Actelion
  • GlaxoSmithKline
  • Bayer
  • Janssen Pharmaceuticals (Johnson & Johnson)
  • Shire
  • Nitto Dento
  • Teva Pharmaceuticals
  • Endo International
  • Boehringer Ingelheim
  • 3M
  • UCB
  • ParPharm

第12章 現在の市販経皮ドラッグデリバリー製品

  • Actavis
  • Actelion
  • GlaxoSmithKline
  • Bayer
  • Mylan Pharmaceuticals
  • Novartis
  • Upsher-Smith
  • Ascend Therapeutics
  • AMAG Pharmaceuticals (Lumara Health)
  • Lavipharm
  • Noven Pharmaceuticals
  • ProStrakan
  • Shire
  • Hercon Pharmaceutical
  • Kremers Urban Pharmaceuticals
  • Nitto Denko
  • Teva Pharmaceutical Industries
  • Endo International
  • Teikoku USA
  • 3M
  • UCB
  • ParPharm

第13章 経皮ドラッグデリバリー市場の詳細なSWOT分析

  • 市場の促進因子
  • 経皮ドラッグデリバリー市場の抑制因子・弱み
  • 市場機会
  • 参入障壁

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 2014TDDM

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 320 tables & figures over 280 pages. This report is presented as follows:

  • By Company (e.g., JANSSEN, MYLAN, ACTAVIS, GLAXOSMITHKLINE, BAYER, NOVARTIS, NOVEN, LAVIPHARM, PROSTRACKEN, NITTO DENTO)
  • By Geography (Global, USA)
  • By Parent Market (Drug Delivery Systems, Advanced Drug Delivery Systems)
  • By Sub-market (Generics, Women's Health, Analgesics, Neuropathic Pain)

A wealth of financial data & business strategy information is provided including:

  • Up-to-date company financials, sales & revenue figures
  • Revenue and market forecasts
  • Business model strategies for drug delivery, pharmaceutical and biotechnology companies
  • Comprehensive account of company products, financials & portfolios

SWOT, Economic & Regulatory Environment specifics include:

  • Key strengths, weaknesses and threats influencing leading player position within the market
  • Technologies driving the market (e.g., chemical enhancers, microneedles)
  • Top fastest growing market segments and emerging opportunities
  • Top pharmaceutical companies within the market
  • Comprehensive product portfolios, R&D activity and pipeline products
  • M&A activity and future strategies of top companies
  • High demand and unmet need enhances the market
  • Challenges of the transdermal drug delivery market

Who should read this report?

  • Pharmaceutical, biotechnology and diagnostic companies with an interest in personalized medicine
  • Industry professionals and business strategists will discover key information to propel their policies
  • Investors will gain inside information to dominant players in the industry and future forecasts
  • Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment

C-Suite professionals, Decision Makers, Business Development professionals

This report will tell you if the companies mentioned are:

  • Strong, competitive players
  • Pooling their resources for specific growth and therapeutic areas
  • Investing strategically in R&D
  • Have a history of strategic M&A activity

This detailed report is supported with 320 figures and tables over 280 pages and profiles the main pharmacos in the transdermal drug delivery market.

Benefits of Investing in our Cutting-Edge Reports:

  • Clients receive complementary content* with mid-level and enterprise wide licences
  • Post-sale complementary consultation with senior expert analyst is included
  • Use of tables and figures in your own reports and presentations is permitted
  • Each report provides straight-talking strategic analysis & sector intelligence
  • All reports are updated each quarter to give you the most up-to-date information

Table of Contents

1.0 Executive Summary

  • 1.1 Objectives of Report
  • 1.2 Data Sources & Methodology
  • 1.3 Key Findings & Observations
    • 1.3.1 The Global Drug Delivery Market has a Growth Rate of 5%
    • 1.3.2 The Transdermal Drug Delivery Market is Growing Vertically
    • 1.3.3 Who are the Leading Players in the Market?
    • 1.3.4 Neurodegenerative Disorders Such as Alzheimer's and Parkinson's Disease Will Propel the Future Market
    • 1.3.5 Why is the Transdermal Drug Delivery Market so Promising?
    • 1.3.6 What are the Main Drivers of the Market?
    • 1.3.7 First, Second and Third Generation Drug Delivery Systems
    • 1.3.8 The Niche Market of Commercially Available Skin Models
    • 1.3.9 Transdermal Drug Delivery Technologies are Providing the Market with Niche Spaces
    • 1.3.10 Nanotechnology is Transforming Transdermal Drug Delivery
    • 1.3.11 Can Transdermal Drug Delivery be Applied to Cancer Vaccination?
    • 1.3.12 Gene Therapy Advancement Using Transdermal Delivery

2.0 Transdermal Drug Delivery

  • 2.1 Introduction
  • 2.2 Developments of Transdermal Drug Delivery to Date
  • 2.3 The Skin - Anatomy and Physiology
    • 2.3.1 Drug Administration via the Intracellular Pathway
    • 2.3.2 Drug Administration via the Intercellular Pathway
    • 2.3.3 Fick's Law
  • 2.4 Factors that Influence Transdermal Drug Delivery
    • 2.4.1 Parameters Influencing Skin Permeability
      • 2.4.1.1 The Vehicle
      • 2.4.1.2 Drug Concentration
      • 2.4.1.3 Partition Coefficient
  • 2.5 Strategies to Enhance Transdermal Drug Delivery
    • 2.5.1 1st Generation Delivery Systems
    • 2.5.2 2nd Generation Delivery Systems
    • 2.5.3 Chemical Enhancers
    • 2.5.4 3rd Generation Delivery Systems
  • 2.6 Comparison of Transdermal Delivery with Other Methods
  • 2.7 Advantages of Transdermal Drug Delivery
    • 2.7.1 First-Pass Metabolism
  • 2.8 Disadvantages of Transdermal Delivery
  • 2.9 Complications of Transdermal Therapy
    • 2.9.1 Overdose
    • 2.9.2 Skin Sensitivity and Reactions
    • 2.9.3 MRI-Induced Skin Burns

3.0 Biomechanical and Pharmacological Elements Effecting Transdermal Drug Delivery

  • 3.1 Factors That Influence Transdermal Drug Delivery
    • 3.1.1 Rate of Permeation Across the Skin
    • 3.1.2 Skin Characteristics
    • 3.1.3 Drug Characteristics
    • 3.1.4 pH and Pharmacokinetics
  • 3.2 Transdermal Drug Design
    • 3.2.1 Factors That Affect the Absorption of the Drug
      • 3.2.1.1 Hydration and Temperature
      • 3.2.1.2 Biotransformation of the Drug in the Skin
    • 3.2.2 Selecting Drug and Vehicle
    • 3.2.3 Drug Modification
      • 3.2.3.2 Ion-Pair Formation
      • 3.2.3.3 Drug Complexation
    • 3.2.4 Thermodynamic Activity of the Drug within the Vehicle
      • 3.2.4.1 Eutectic Systems
      • 3.2.4.2 Vehicle Formulation
      • 3.2.4.3 Modification of the Stratum Corneum
  • 3.3.1 Static Franz Diffusion Cell
  • 3.4 Commercially Available Skin Models for Transdermal Drug Testing
  • 3.5 In vivo Testing of Transdermal Drug Delivery Systems
    • 3.5.1 In vivo Testing of Drug Delivery Systems
    • 3.5.2 Modelling of Transport Through the Skin

4.0 Transdermal Drug Delivery Technologies

  • 4.1 Introduction
    • 4.1.1 Local Application Formulations
    • 4.1.2 Liquid Crystals for Transdermal Drug Delivery
    • 4.1.3 Microemulsions for Transdermal Drug Delivery
    • 4.1.4 Nanoemulsions for Transdermal Drug Delivery
    • 4.1.5 Transdermal Gel Technology
    • 4.1.6 Biphasix System
    • 4.1.7 Penetration Enhancers
    • 4.1.8 Chemical Enhancers
    • 4.1.9 Nitric Oxide-Based Transdermal Drug Delivery
  • 4.2 Vesicular transdermal carriers
    • 4.2.1 Liposomes
    • 4.2.2 Transfersomes
    • 4.2.3 Ethosomes
    • 4.2.4 Elastic Vesicles
  • 4.3 Transdermal Patch
    • 4.3.1 Types of Transdermal Patch
      • 4.3.1a Single-layer Drug-in-Adhesive
      • 4.3.1b Multi-layer Drug-in-Adhesive
      • 4.3.1c Reservoir
      • 4.3.1d Matrix Patch
      • 4.3.1e Vapour Patch
    • 4.3.1 Transdermal Patches Adhesives
    • 4.3.2 New Technologies
    • 4.3.3 h-Patch™ Controlled Release Micropump System
  • 4.4 Patchless Transdermal Delivery System
  • 4.5 Metered-Dose Transdermal System
  • 4.6 Polymers for Transdermal Drug Delivery
    • 4.6.2 Film Forming Polymeric Solutions
  • 4.7 Physical Methods to Promote Transdermal Delivery
    • 4.7.1 Electrotransport
    • 4.7.2 Electroporation
      • 4.7.2.1 Drug delivery by Electroporation
      • 4.7.2.2 Electrochemotherapy
    • 4.7.3 Cryoelectrophoresis
    • 4.7.4 Iontophoresis
      • 4.7.4.1 Application of Iontophoresis for Drug Delivery
      • 4.7.4.2 Companies with Technologies for Drug Delivery by Iontophoresis
  • 4.8 How Combining Electrophoresis and Iontophoresis Impacts Drug Delivery
  • 4.9 Dermaportation
    • 4.9.1 Radiofrequency-Driven Transdermal Delivery
    • 4.9.2 Transcutaneous Drug Delivery by Electropulsation
    • 4.9.3 Skin Patch Systems and Electrostatic Force
    • 4.9.4 Heat-Aided Drug Delivery
    • 4.9.5 Ultrasound
    • 4.9.6 Magnetophoresis
  • 4.10 Use of Lasers for Transdermal Drug Delivery
    • 4.10.1 Laser-Induced Microporation
    • 4.10.2 Painless Laser Injection
    • 4.10.3 Laser-Induced Pressure Waves
      • 4.10.3.1 Transdermal Drug Delivery by Laser-Assisted Changes in Skin
  • 4.11 How Pressurized Gas is Transforming Transdermal Drug Delivery
  • 4.12 Microscission Induced by Gas
  • 4.13 Role of Microelectromechanical Systems (MEMS) in Transdermal Drug Delivery
  • 4.14 Microneedles and Dermal Microinjection
  • 4.15 Microneedle Arrays for Drug Delivery
    • 4.15.1 Microneedle Patch
    • 4.15.2 Applications of Microneedles
    • 4.15.3 AdminPatch® Microneedle Array
    • 4.15.4 Dissolving Microneedles
  • 4.16 Biodegradable Microneedles
  • 4.17 Ceramic Microneedle Arrays
  • 4.18 Dissolvable Microneedle Patches
    • 4.18.1 MicorCor
    • 4.18.2 MicroPyramid™
  • 4.19 Microstructured Transdermal Systems
  • 4.20 Microneedle Transdermal Chip
  • 4.21 Microneedle Applicator Device
  • 4.22 DebioJect ™ Microneedle Technology
  • 4.23 Silk Microneedles
  • 4.24 Tattooing
  • 4.25 ZP Patch Microprojections Technology
  • 4.26 Other Microneedle Products Currently Available
  • 4.27 Needlefree injections
  • 4.28 Glide SDI® Solid Dose Injector
  • 4.29 Jet Injection
    • 4.29.1 Why is Needle-Free so Important?
    • 4.29.2 Mini-Ject Needlefree Delivery System
    • 4.29.3 PharmaJet Stratis
    • 4.29.4 MicroJet for Painless Injections
    • 4.29.5 Nanoliter-Volume Pulsed Microjets
  • 4.30 SUMAVEL™ DosePro™ Needle-Less Injection
    • 4.31 Skin Abrasion

5.0 How Nanotechnology is Transforming Transdermal Drug Delivery

  • 5.1 Overview
  • 5.2 Nanotechnology-Based Transdermal Drug Delivery
    • 5.2.1 Nanobiotechnology for Transdermal Application
  • 5.3 Nanoparticles and Nanoemulsions for Skin Disorders
  • 5.4 Nanopatches
    • 5.4.1 Vaxxas Nanopatch Technology
    • 5.4.2 Effect of Mechanical Flexion on Penetration of Bucky Amino Acids Through the Skin
  • 5.5 Inocyte™ Epidermal Drug Delivery System
  • 5.6 Ionic Nanoparticle Technology
  • 5.7 Solid Lipid Nanoparticles (SLN) Gels
  • 5.8 siRNA- Nanoparticle Conjugates
  • 5.9 Transdermal Nanoparticle Preparations for Systemic Effect
  • 5.10 Micellar Nanoparticle Estradiol Emulsion (MNPEE)
  • 5.11 Transferosomes
  • 5.12 Nanocarriers
  • 5.13 Nanotechnology for Vaccination and Immunotherapy
  • 5.14 Safety Issues of Applications of Nanomaterial Carriers on the Skin
  • 5.15 Comparison of Current Transdermal Drug Delivery Systems

6.0 Transdermal Drug Delivery and Disease States

  • 6.1 Antiaging Products
  • 6.2 Cancer
    • 6.2.1 δ-Amino Levulinic Acid
    • 6.2.2 Breast Cancer & Afimoxifene Gel
    • 6.2.3 Cervical Cancer & Interferon α2b
    • 6.2.4 Prostate Cancer & Nitroglycerine
    • 6.2.5 Prostate Cancer & Estradiol Gel
    • 6.2.6 Prostate Cancer & Leuprolide Acetate
    • 6.2.7 Skin Cancer & Caffeine
    • 6.2.6 Cancer Vaccines
      • 6.2.6.1 Intradermal Delivery Using Adenoviral Vectors
      • 6.2.6.2 Peptide Cancer Vaccines
      • 6.2.6.3 Electroporation of Anticancer Agents
  • 6.3 Cardiovascular Disease
    • 6.3.1 Transdermal Anticoagulants
    • 6.3.2 Angina Pectoris
    • 6.3.3 Atherosclerotic Cardiovascular Disease
      • 6.3.3.1 Transdermal Oestrogen for Prevention of Atherosclerotic Cardiovascular Disease
    • 6.3.4 Congestive Heart Failure
    • 6.3.5 Hypertension
      • 6.3.5.1 Clonidine
      • 6.3.5.2 β-Blockers
      • 6.3.5.3 Calcium Channel Blockers
  • 6.4 Chronic Fatigue Syndrome
  • 6.5 Contraception
    • 6.5.1 Female Contraception
      • 6.5.1.1 Agile Therapeutics AG200-15
      • 6.5.1.2 BAY86-5016 / FC Patch Low BAY86-5016
      • 6.5.1.3 Desogestrel
      • 6.5.1.4 Ortho Evra™
    • 6.5.2 Male Contraception
      • 6.5.2.1 Transdermal Progestin Plus Testosterone
  • 6.6 Diabetes
    • 6.6.1 Insulin Drug Delivery
      • 6.6.1.1 V-Go
      • 6.6.1.2 GLP1 Agonist
  • 6.7 Men's Health
    • 6.7.1 Benign Prostatic Hypertrophy
      • 6.7.1.2 Tamsulosin Transdermal Drug Delivery System
    • 6.7.2 Erectile Dysfunction
      • 6.7.2.1 Topical and Transdermal Preparation for Erectile Dysfunction
    • 6.7.3 Hypogonadism
      • 6.7.3.1 Topical Testosterone
  • 6.8 Musculoskeletal Disease
    • 6.8.1 Osteoarthritis
    • 6.8.2 Osteoporosis
      • 6.8.2.1 Alendronate
      • 6.8.2.2 Estrogen
      • 6.8.2.3 Human Parathyroid Hormone
  • 6.9 Nausea and Vomiting
    • 6.9.1 Chemotherapy-Induced
    • 6.9.2 Motion Sickness
    • 6.9.3 Postoperative Vomiting
  • 6.10 Neurological Disease
    • 6.10.1 Alzheimer's Disease
      • 6.10.1.1 Arecoline
      • 6.10.1.2 Rivastigmine
      • 6.10.1.3 Donepezil
  • 6.11 Attention Deficit Hyperactivity Disorder
    • 6.11.1 Methylphenidate
  • 6.12 Bipolar Disorder
    • 6.12.1 Lithium
  • 6.13 Depression
    • 6.13.1 Antidepressants
    • 6.13.2 Selective Serotonin-Reuptake Inhibitors
    • 6.13.3 Fluoxetine
    • 6.13.4 Monoamine Oxidase Inhibitors
    • 6.13.5 Selegiline
    • 6.13.6 Trazodone Hydrochloride
    • 6.13.7 Venlafaxine
    • 6.13.8 Bupropion
  • 6.14 Epilepsy
  • 6.15 Migraine
    • 6.15.1 Sumatriptan
    • 6.15.2 Zolmitriptan
  • 6.16 Parkinson's Disease
    • 6.16.1 Introduction
    • 6.16.2 Dopamine Agonists
      • 6.16.2.1 Levodopa
      • 6.16.2.2 Rotigotine
    • 6.16.3 Other Agents
  • 6.17 Restless Leg Syndrome
    • 6.17.1 Rotigotine
  • 6.18 Schizophrenia
    • 6.18.1 Haloperidol
    • 6.18.2 Risperidone
    • 6.18.3 Blonanserin
  • 6.19 Tinnitus/Vertigo
    • 6.22.1 Nicotine
  • 6.20 Tourette syndrome
  • 6.21 Multiple Sclerosis
  • 6.22 Respiratory diseases
    • 6.22.1 Asthma and Chronic Obstructive Pulmonary Disease (COPD)
  • 6.23 Skin disorders
    • 6.23.1 Cutaneous Leishmaniasis
    • 6.23.2 Hair Loss
    • 6.23.3 Iontophoretic Drug Delivery for Nail Disorders
    • 6.23.4 Psoriasis
    • 6.23.4.1 Nanoemulsions for Paxitacel in Psoriasis
    • 6.23.4.2 Iontophoresis for Treatment of Psoriasis
  • 6.24 Overactive Bladder and Urinary Incontinence
    • 6.24.1 Oxybutynin
  • 6.25 Pain
    • 6.25.1 Chronic Pain
    • 6.25.2 Transdermal Local Anesthetics
    • 6.25.3 Transdermal Fentanyl for the Management of Postoperative Pain
    • 6.25.4 Fibromyalgia
    • 6.25.5 Minor Medical Procedures
    • 6.25.6 Neuralgia
    • 6.25.6.1 Lidoderm
    • 6.25.7 Nonsteroidal Anti-Inflammatory Drugs
    • 6.25.7.1 Topical NSAIDs
    • 6.25.8 Ketoprofen
    • 6.25.9 Opioids
    • 6.25.10 Cancer Pain
    • 6.25.10.1 Fentanyl
    • 6.25.10.2 Nitroglycerine
    • 6.25.10.3 Buprenorphine
  • 6.26 Smoking Cessation
    • 6.26.1 Nicotine Replacement Therapy
    • 6.26.2 Nicotine Patch in Pregnancy
  • 6.27 Viral infections
    • 6.27.1 Transdermal Nanoparticles for Immune Enhancement in HIV
  • 6.28 Women's Health
    • 6.28.1 Dysmenorrhea
    • 6.28.2 Female Infertility
    • 6.28.3 Female Sexual Arousal Disorder
    • 6.28.4 Menopause
    • 6.28.4.1 Hormone Replacement Therapy
    • 6.28.5.2 Estradiol
    • 6.28.5.3 Parathyroid Hormone for Postmenopausal Osteoporosis
    • 6.28.5.4 Testosterone and Low Libido
  • 6.29 Transdermal Nutraceuticals

7.0 Gene Therapy and Transdermal Drug Delivery

  • 7.1 Overview
  • 7.2 Plasmid DNA and Electroporation
    • 7.2.1 TriGrid™ Delivery System
    • 7.2.2 CELLECTRA®
    • 7.2.3 Magnetic Pulse Electroporation
  • 7.3 Antisense Therapy

8.0 Vaccines and Transdermal Drug Technology

  • 8.1 Introduction
    • 8.1.1 The Skin as an Immune Organ
    • 8.1.1.1 Langerhans Cells- Epidermal Antigen Presenting Cells
    • 8.1.1.2 Keratinocytes- Immune Competent Epithelial cells
    • 8.1.1.3 Dendritic Epidermal T Cells (DETC) γδ T cells -Specialised Resident Epithelial Cells
    • 8.1.1.4 Epidermotropic T lymphocytes-Circulating T Cells that home to the Epidermis
    • 8.1.1.5 Melanocytes-Epidermal Pigment Cells With Immune Properties
  • 8.2 Current Technologies
    • 8.2.1 Dissolvable Microneedle Array
    • 8.2.2 Electroporation for Administering DNA Vaccines
    • 8.2.3 Microneedles for Transdermal Vaccine Delivery
    • 8.2.4 Needle-Free Delivery of Vaccines
  • 8.3 Applications for Transdermal Vaccination
    • 8.3.1 HIV/AIDS Vaccine
    • 8.3.2 Transdermal DNA Influenza Vaccine
    • 8.3.3 Transdermal Aβ Vaccine for Alzheimer's Disease
    • 8.3.4 Transdermal Vaccine for Traveller's Diarrhoea

9.0 Global Drug Delivery Market

  • 9.1 Overview and Analysis
  • 9.2 USA Drug Delivery Market
  • 9.3 European Drug Delivery Market
  • 9.4 Emerging Drug Delivery Markets
  • 9.5 The Advanced Drug Delivery Landscape
  • 9.6 Transdermal Drug Delivery Market
  • 9.7 Smoking Cessation Drug Market
    • 9.7.1 Nicotine Replacement Therapeutics
    • 9.7.2 Non-Nicotine Containing Therapeutics
    • 9.7.3 Smoking Cessation Products in the Pipeline
  • 9.8 Neurodegenerative Disorders Such as Alzheimer's & Parkinson's disease will Propel the Future Market
  • 9.9 How Transdermal Systems Relate to the Global Pain Market
    • 9.9.1 Neuropathic Pain Market (US, UK, France, Germany, Japan, Spain and Italy) 2014-2020
    • 9.9.2 Transdermal Products Within the Neuropathic Pain Market
  • 9.10 How Transdermal Systems Relate Within the Generic Market
  • 9.11 Duragesic and Generic Fentanyl Transdermal System Competition
  • 9.12 Lidocaine Market Analysis
  • 9.13 Who are the Leading Players in the Market?
  • 9.14 What is Driving the Transdermal Drug Delivery Market?
  • 9.15 Increased Number of Geriatric and Pediatric Patients is Propelling the Market
  • 9.16 Unmet Needs Within the Transdermal Drug Delivery Market
  • 9.17 Women's Health Market

10.0 Transdermal Drug Delivery Company Business Profiles and Strategic Evaluation

  • 10.1 Actavis
  • 10.2 Actelion
  • 10.3 GlaxoSmithKline
  • 10.4 Bayer
  • 10.5 Mylan Pharmaceuticals
  • 10.6 Novartis
  • 10.7 Upsher-Smith
  • 10.8 Ascend Therapeutics
  • 10.9 AMAG Pharmaceuticals (Lumara Health, KV Pharma/Ther-Rx Corp)
  • 10.10 Janssen Pharmaceuticals
  • 10.11 Noven Pharmaceuticals
  • 10.12 ProStrakan
  • 10.13 Shire
  • 10.14 Hercon Pharmaceutical
  • 10.15 Kremers Urban Pharmaceuticals
  • 10.16 Nitto Denko
  • 10.17 Teva Pharmaceutical Industries
  • 10.18 Endo International
  • 10.19 Teikoku USA
  • 10.20 Boehringer Ingelheim
  • 10.21 3M
  • 10.22 UCB
  • 10.23 ParPharm

11.0 Transdermal Drug Delivery Company Financial Analysis

  • 11.1 Actavis
  • 11.2 Actelion
  • 11.3 GlaxoSmithKline
  • 11.3.1 ViiV Healthcare
  • 11.4 Bayer
  • 11.5 Janssen Pharmaceuticals (Johnson & Johnson)
  • 11.6 Shire
  • 11.7 Nitto Dento
  • 11.8 Teva Pharmaceuticals
  • 11.9 Endo International
  • 11.10 Boehringer Ingelheim
  • 11.11 3M
  • 11.12 UCB
  • 11.13 ParPharm

12.0 Current Transdermal Drug Delivery Products on the Market

  • 12.1 Actavis
    • 12.1.1 Androderm
    • 12.1.2 Fentanyl Transdermal System
    • 12.1.3 Lidocaine Topical Patch
    • 12.1.4 Oxytrol
  • 12.2 Actelion
    • 12.2.1 Vachlor Gel (mechlorethamine)
  • 12.3 GlaxoSmithKline
    • 12.3.1 Niquitin/Nicoderm
  • 12.4 Bayer
  • 12.5 Mylan Pharmaceuticals
    • 12.5.1 Clonidine Transdermal System
    • 12.5.2 EMSAM (Selegiline Transdermal System)
    • 12.5.3 Estradiol Transdermal System
    • 12.5.4 Fentanyl Transdermal System
    • 12.5.5 Nitroglycerin Transdermal System
    • 12.5.6 XULANE (Norelgestromin / Ethinyl Estradiol Transdermal System)
  • 12.6 Novartis
    • 12.6.1 Exelon Patch (Rivastigmine Transdermal System)
    • 12.6.2 Duragesic - Fentanyl Patches
    • 12.6.3 Transderm Scop - Scopolamine Patches
  • 12.7 Upsher-Smith
    • 12.7.1 Vogelxo - Testosterone (1%) Gel
  • 12.8 ASCEND Therapeutics
    • 12.8.1 EstroGel®
  • 12.9 AMAG Pharmaceuticals (Lumara Health)
    • 12.9.1 Evamist®
  • 12.10.1 OrthoEvra®
    • 12.10.2 Duragesic®
  • 12.11 Lavipharm
    • 12.11.1 Fentadur
    • 12.11.2 Nicotine Transdermal Patch
    • 12.11.3 Acne Transdermal Patch
    • 12.11.4 Trinipatch
  • 12.12 Noven Pharmaceuticals
    • 12.12.1 Minivelle®
    • 12.12.2 CombiPatch®
    • 12.12.3 Daytrana®
  • 12.13 ProStraken
    • 12.13.1 Sancuso®
  • 12.14 Shire
    • 12.14.1 Daytrana® CII
  • 12.15 Hercon Pharmaceuticals
    • 12.15.1 Nitroglycerin Transdermal System
  • 12.16 Kremers Urban Pharmaceuticals
    • 12.16.1 Nitroglycerin Transdermal System
  • 12.17 Nitto Dento
    • 12.17.1 Bisono Tape
    • 12.17.2 Penles Tape
    • 12.17.3 Passport Advanced Drug Delivery System
  • 12.18 Teva Pharmaceuticals
    • 12.18.1 Zecuity
    • 12.18.2 Transdermal Fentanyl (generic)
    • 12.18.3 Tev Tropin
  • 12.19 Endo International
    • 12.19.1 Lidoderm®Patch
    • 12.19.2 Fortesa Gel
  • 12.20 Teikoku
    • 12.20.1 Lidoderm® 1
    • 12.20.2 IontoPatch®
  • 12.21 3M
    • 12.21.1 3M Fentanyl Transdermal Delivery System
    • 12.21.2 3M Rivastigmine Transdermal Delivery System
    • 12.21.3 Microneedles
  • 12.22 UCB
    • 12.22.1 Neupro®
  • 12.23 ParPharm
    • 12.23.1 Fentanyl Transdermal System

13.0 In-Depth SWOT Analysis of the Transdermal Drug Delivery Market

  • 13.1 Drivers of the Market
    • 13.1.1 Patent Expirations and Introduction of Generics
    • 13.1.2 Increased Patient Compliance Rates
    • 13.1.3 Increased Rate of Chronic Conditions and Application of Patch Technology to These Areas
    • 13.1.4 Increased Geriatric and Pediatric Drug Administration Requirements
  • 13.2 Restraints and Weaknesses of the Transdermal Drug Delivery Market
    • 13.2.1 Technical Restraints
    • 13.2.2 Drug Adverse Reactions
    • 13.2.3 Drug Failures
  • 13.3 Opportunities Within the Market Place
    • 13.3.1 High number of Pharmaco & Drug Delivery Company Collaboration
    • 13.3.2 Increasing Indications and Disease States for Transdermal Administration
    • 13.3.3 Large Opportunity for Home Health Care Market and OTC
    • 13.3.4 Targeted Drug Delivery
  • 13.4 Barriers to Market Entry
Back to Top